Physician profile
Devin L Dickson
NPI 1932543220
$828.47
in general payments reported to CMS, 2019-2025
14 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $61.09 · 2024: $566 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.87 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $130.69 | 2023-2024 | Arexvy, Shingrix |
| Shield Therapeutics INC | $121.47 | 2024 | |
| Lilly USA, LLC | $79.02 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.01 | 2024-2025 | Xifaxan |
| Abbvie INC. | $52.46 | 2025 | |
| Exact Sciences Corporation | $44.13 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $41.94 | 2024-2025 | Freestyle Libre 3, Proclaim |
| Kowa Pharmaceuticals America, INC. | $34.47 | 2024-2025 | Livalo, Zoryve |
| Astrazeneca Pharmaceuticals LP | $21.65 | 2025 | Airsupra |
| Pfizer INC. | $15.95 | 2025 | |
| Dexcom, INC. | $15.69 | 2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $13.83 | 2024 | Xyosted |
| Amgen INC. | $13.29 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.